Physician profile
Li Liang
NPI 1912994567
$2,093.28
in general payments reported to CMS, 2019-2025
17 companies · $500 in 2025
The $500 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $78.28 · 2021: $60.07 · 2022: $110 · 2023: $391 · 2024: $718 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $589.96 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $367.60 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $181.72 | 2023-2025 | Dupixent |
| Amgen INC. | $134.87 | 2023-2025 | Tezspire |
| Abbvie INC. | $133.88 | 2023-2024 | |
| Blueprint Medicines Corporation | $119.70 | 2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $119.69 | 2023-2025 | Takhzyro, Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $113.32 | 2025 | |
| Pfizer INC. | $97.09 | 2023-2025 | |
| Csl Behring | $52.64 | 2025 | Hizentra, Andembry |
| Genzyme Corporation | $42.02 | 2025 | |
| Grifols USA, LLC | $31.83 | 2024 | Xembify |
| Gc Biopharma USA, INC. | $29.96 | 2025 | Alyglo |
| Biocryst US Sales Co., LLC | $25.03 | 2024 | Orladeyo |
| Galderma Laboratories, L.P. | $19.53 | 2025 | Nemluvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $19.06 | 2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $15.38 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.